Condition
Bilirubin Encephalopathy
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Terminated1
Active Not Recruiting1
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04584983Phase 2Active Not RecruitingPrimary
Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration
NCT03534466Not ApplicableTerminated
Evaluation of Long-Term Gait Development in Infants With Neonatal Encephalopathy Using Infant Treadmill
NCT03527498Not ApplicableWithdrawn
Evaluation of Long-term Neurodevelopment in Neonatal Encephalopathy by Infant Treadmill
Showing all 3 trials